Recombinant, Bivalent, Norovirus Vaccine Study
Condition: Norovirus Interventions: Biological: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg); Biological: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg); Drug: Placebo Sponsors: Icon Genetics GmbH; University Hospital, Ghent Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials